Precision Epigenomics and DVRGNT Ventures: A Partnership to Revolutionize Early Cancer Detection

DVRGNT Ventures proudly marks its first investment in Precision Epigenomics, a pioneering biotech company committed to early cancer detection through breakthrough liquid biopsy technology.

Early last year, we at DVRGNT Ventures set out to redefine venture capital investing by focusing on diverse communities and disruptive technologies. This year, we made our first investment and found a perfect match in Precision Epigenomics (PE). As DVRGNT's first portfolio company, Precision Epigenomics exemplifies the power of innovation and diversity through its cutting-edge cancer detection solutions.

We sat down with Mark Nelson, the co-founder and CEO of Precision Epigenomics, for a deeper dive into his journey, the company’s mission, and how this exciting partnership came to life.

From Idea to Innovation: Precision Epigenomics' Mission

“Some of my family members have passed away from cancer, and it has been a driving force for me…” Mark's journey began with personal commitment to changing the world of cancer diagnostics “If some of the technology we now have had existed earlier, maybe they’d still be with us.”. Growing up in a large family, several of whom battled cancer, Mark developed a passion for creating better solutions for cancer diagnostics.

This vision became a reality in 2019 when Mark, alongside Dr. Bernard Futscher, co-founded Precision Epigenomics. What started as university research soon transformed into EPISEEK™, a breakthrough multi-cancer detection test. With just a simple blood draw, the test detects over 25 types of cancers early—when treatment is most effective.

Their work is rooted in machine learning algorithms and bioinformatics, helping them identify cancer signals that traditional methods miss. “The more data we provide clinicians, the better their decisions can be,” Mark said. The launch of EPISEEK™ earlier in 2024 marks a significant milestone, placing Precision Epigenomics at the forefront of cancer diagnostics.

Why DVRGNT Ventures and Precision Epigenomics Aligned

The partnership between DVRGNT and Precision Epigenomics is much more than a financial investment—it's a shared mission to empower diverse voices and deliver impactful innovations. Mark reflected on his first conversation with DVRGNT Ventures partners (B. and Jeremy), he discusses how “We didn’t talk about business at first; we talked about who we were and what mattered to us.”

This connection resonated with DVRGNT’s core values of diversity, inclusion, and accessibility. Both parties share a commitment to making healthcare innovations available to all communities, especially those that have historically been underserved. “Our liquid biopsy could help combat healthcare disparities by increasing access to state-of-the-art diagnostics,” Mark emphasized. However, as Mark acknowledged, more work is needed to make such tests affordable and covered by insurance.

Building a Strong Foundation: The Team Behind the Innovation

 Behind every successful startup is a well-rounded team. “We’ve built a strong network of talented individuals, and each person contributes to advancing our mission.” Mark spoke with pride about his executive team and scientific advisors, including experts from institutions like the University of Arizona.

Mark highlighted the importance of human, financial, and social capital in building Precision Epigenomics. PE was successful in securing two Small Business Innovation Research (SBIR) grants from the National Cancer Institute was a pivotal moment. “Those grants gave us external validation—proof that we were on the right track,” Mark explained.

Overcoming Challenges and Changing Perceptions

Despite the company’s success, Precision Epigenomics has not been immune to skepticism, especially in a post-Theranos world. “Many companies in the liquid biopsy space have faced doubts,” Mark admitted. “But we rely on scientific rigor, peer-reviewed studies, and partnerships to build credibility.”

Precision Epigenomics has developed strategic collaborations, including partnerships with TruDiagnostic and Baylor College of Medicine, to expand the use of EPISEEK™ globally. Mark envisions a future where the test not only detects cancer early but also guides treatment decisions and monitors patients after recovery.

The Power of Persistence: Advice for Minority Founders

As a minority founder in biotech, Mark understands the challenges that come with navigating a specialized field. His advice to aspiring entrepreneurs from underrepresented backgrounds is clear: "Believe in yourself and your mission. Mistakes will happen—learn from them and keep moving forward."

As Mark reflects on his journey, he refers to his upbringing in Tulsa, Oklahoma, where entrepreneurship was encouraged despite historical setbacks. "In the words of the late Congressman John Lewis, make good trouble," Mark said, a sentiment that resonates deeply with DVRGNT’s mission of breaking barriers and the opportunities that are available in “The Great 38”

Looking Ahead: Expanding the Reach of Precision Epigenomics

Mark’s excitement for the future is palpable. Precision Epigenomics is already exploring new applications for their technology beyond cancer detection. Mark strongly believes that “Liquid biopsy could help doctors choose the right therapies or monitor patients after treatment.”.

As they look to expand globally, Mark remains committed to accessibility and inclusion aiming “to work with partners who serve underrepresented communities, ensuring that everyone can benefit from our innovations."

A Shared Vision for Impact

The partnership between DVRGNT Ventures and Precision Epigenomics is a testament to the power of diverse leadership and transformative technology. Together, we are paving the way for a future where earlier cancer detection becomes the norm, not the exception.

Through hard work, innovative science, and a commitment to inclusion, Precision Epigenomics exemplifies the kind of impact-driven companies that DVRGNT seeks to champion. Mark’s journey reminds us all that even in the face of challenges, persistence and belief in a mission can change the world—one test at a time.